Janka Jenčová
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Janka Jenčová has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Adriána Petrášová
Clinic of Dentistry and Maxillofacial Surgery, Academy of Košice, Pavol Jozef Šafárik University, Košice, Slovakia
4 shared publications - Andrej Jenča
Academy of Košice, Pavol Jozef Šafárik University, Solmea s.r.o., Bačíkova 7, 04001 Košice, Slovakia
4 shared publications - Elham Saberian
Clinic of Stomatology and Maxillofacial Surgery, Academy of Košice, Pavol Jozef Šafárik University
4 shared publications - Hadi Zare-Zardini
Department of Biomedical Engineering, Meybod University, Meybod, Iran
4 shared publications - Andrej Jenča
Clinic of Dentistry and Maxillofacial Surgery, Academy of Košice, Pavol Jozef Šafárik University, Košice, Slovakia
3 shared publications - Mieszko Wieckiewicz
Department of Experimental Dentistry, Wroclaw Medical University, 50-425 Wroclaw, Poland
3 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Wroclaw Medical University in Dental and Medical Problems
- No. 6
Effect of implant placement on the expression of osteogenic genes in the root of the adjacent tooth: An animal study
- 15 October 2026
- Published by Wroclaw Medical University in Dental and Medical Problems
- No. 6
Open AccessEffect of implant placement on the expression of osteogenic genes in the root of the adjacent tooth: An animal study
- Open Access
- 17 June 2026
- Published by Wroclaw Medical University in Dental and Medical Problems
- No. 5,p. 1243-1258
HAp–ZrO2–AgNP-reinforced polystyrene dental nanocomposites: Antibacterial, antiplaque and self-cleaning properties
Dental biofilms, primarily driven by Streptococcus mutans, are the main etiological agents of caries and restorative failure. The aim of the study was to design and synthesize a novel polystyrene (PS)-based nanocomposite reinforced with hydroxyapatite (HAp), zirconia (ZrO2) and silver nanoparticles (AgNPs). Hydroxyapatite, ZrO2 and AgNPs were synthesized via wet precipitation, sol-gel and citrate reduction methods, respectively. The nanoparticles (5 wt% total loading) were uniformly dispersed in a toluene-based PS matrix using ultrasonic-assisted solution casting. The resulting films were characterized in terms of morphology (scanning electron microscopy (SEM), transmission electron microscopy (TEM), atomic force microscopy (AFM)), composition (energy-dispersive X-ray spectroscopy (EDX)), thermal stability (thermogravimetric analysis (TGA)), mechanical properties (tensile strength, Young's modulus, Vickers hardness), surface wettability (water contact angle (WCA)), antibacterial efficacy (zone of inhibition (ZOI), minimum inhibitory concentration/minimum bactericidal concentration (MIC/MBC), colony-forming unit (CFU) assay), and antibiofilm activity (crystal violet staining, confocal laser scanning microscopy (CLSM)). Statistical analysis was performed using one-way analysis of variance (ANOVA) and Tukey's honestly significant difference (HSD) test (p < 0.05). The nanocomposite exhibited a 30% increase in tensile strength (32.5 MPa vs. 25 MPa for pure PS) and a 25% rise in elastic modulus (1.5 GPa vs. 1.2 GPa). The water contact angle increased from 85° ±2° (pure PS) to 115° ±3° (nanocomposite), confirming significantly enhanced hydrophobicity. The composite demonstrated strong antibacterial activity, with a ZOI of 15.3 mm, MIC of 6.25 mg/mL, MBC of 12.5 mg/mL, and 99.8% bacterial reduction within 24 h. Antibiofilm performance was also notable, showing a 91.2% reduction in biofilm biomass after 72 h and 74.8% decrease in biofilm thickness (from 32.5 μm to 8.2 μm). Confocal laser scanning microscopy revealed a marked shift in the live/dead cell ratio (from 4.7:1 to 0.6:1), confirming bactericidal rather than bacteriostatic action. All nanoparticles were homogeneously distributed without agglomeration, as confirmed by SEM/EDX and TEM. The HAp-ZrO2-AgNP-reinforced PS nanocomposite integrates enhanced mechanical properties, self-cleaning surface characteristics, and potent, long-lasting antibiofilm activity against S. mutans. While further biocompatibility and clinical translation studies are warranted, this material represents a significant leap toward durable, infection-resistant dental applications.
- 17 June 2026
- Published by Wroclaw Medical University in Dental and Medical Problems
- No. 5,p. 1243-1258
Open AccessHAp–ZrO2–AgNP-reinforced polystyrene dental nanocomposites: Antibacterial, antiplaque and self-cleaning properties
Dental biofilms, primarily driven by Streptococcus mutans, are the main etiological agents of caries and restorative failure. The aim of the study was to design and synthesize a novel polystyrene (PS)-based nanocomposite reinforced with hydroxyapatite (HAp), zirconia (ZrO2) and silver nanoparticles (AgNPs). Hydroxyapatite, ZrO2 and AgNPs were synthesized via wet precipitation, sol-gel and citrate reduction methods, respectively. The nanoparticles (5 wt% total loading) were uniformly dispersed in a toluene-based PS matrix using ultrasonic-assisted solution casting. The resulting films were characterized in terms of morphology (scanning electron microscopy (SEM), transmission electron microscopy (TEM), atomic force microscopy (AFM)), composition (energy-dispersive X-ray spectroscopy (EDX)), thermal stability (thermogravimetric analysis (TGA)), mechanical properties (tensile strength, Young's modulus, Vickers hardness), surface wettability (water contact angle (WCA)), antibacterial efficacy (zone of inhibition (ZOI), minimum inhibitory concentration/minimum bactericidal concentration (MIC/MBC), colony-forming unit (CFU) assay), and antibiofilm activity (crystal violet staining, confocal laser scanning microscopy (CLSM)). Statistical analysis was performed using one-way analysis of variance (ANOVA) and Tukey's honestly significant difference (HSD) test (p < 0.05). The nanocomposite exhibited a 30% increase in tensile strength (32.5 MPa vs. 25 MPa for pure PS) and a 25% rise in elastic modulus (1.5 GPa vs. 1.2 GPa). The water contact angle increased from 85° ±2° (pure PS) to 115° ±3° (nanocomposite), confirming significantly enhanced hydrophobicity. The composite demonstrated strong antibacterial activity, with a ZOI of 15.3 mm, MIC of 6.25 mg/mL, MBC of 12.5 mg/mL, and 99.8% bacterial reduction within 24 h. Antibiofilm performance was also notable, showing a 91.2% reduction in biofilm biomass after 72 h and 74.8% decrease in biofilm thickness (from 32.5 μm to 8.2 μm). Confocal laser scanning microscopy revealed a marked shift in the live/dead cell ratio (from 4.7:1 to 0.6:1), confirming bactericidal rather than bacteriostatic action. All nanoparticles were homogeneously distributed without agglomeration, as confirmed by SEM/EDX and TEM. The HAp-ZrO2-AgNP-reinforced PS nanocomposite integrates enhanced mechanical properties, self-cleaning surface characteristics, and potent, long-lasting antibiofilm activity against S. mutans. While further biocompatibility and clinical translation studies are warranted, this material represents a significant leap toward durable, infection-resistant dental applications.
- Open Access
- 27 May 2026
- Published by Wroclaw Medical University in Dental and Medical Problems
- No. 5,p. 1155-1166
Oral microbiota diversity and composition in patients with oral lichen planus: An observational molecular analysis study
Oral lichen planus (OLP) is a chronic inflammatory condition affecting the oral mucosa. The oral microbiome has been identified as a potential contributing factor to OLP. The aim of the study was to evaluate the prevalence and diversity of the oral microbiota in patients with OLP. This observational study included 78 patients with clinically and histopathologically confirmed OLP, recruited in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Buccal mucosa samples were collected using standardized protocols. DNA was extracted from 12 high-quality samples and subjected to 16S rRNA gene amplification and sequencing. Alpha and beta diversity indices were calculated using the Quantitative Insights Into Microbial Ecology (QIIME) platform. Statistical analyses were performed using the IBM SPSS Statistics for Windows software, v. 26.0 (IBM Corp., Armonk, USA) (p < 0.05). Intratissue bacterial communities exhibited decreased alpha diversity and increased beta diversity compared with those present on the mucosal surface. Streptococcus, a genus within the Firmicutes phylum, was found to be the most abundant, with 5 Streptococcus strains identified in the OLP samples. Following Streptococci, Bacilli and Clostridia displayed considerable diversity. Other frequently detected species included Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Eikenella corrodens, Actinobacillus, as well as members of the Proteobacteria phylum, which are commonly found in high quantities in the oral cavity. Prevotella and Capnocytophaga, belonging to the Bacteroidetes phylum, were also frequently observed. Alpha diversity analysis revealed significant differences in the colony numbers of the investigated species across studied samples. The findings indicate an association between the composition of the oral microbiota and OLP. The microbial populations obtained from affected individuals exhibited distinct bacterial compositions. Modulation of the oral microbiome may represent a potential strategy for improving the management of OLP.
- 27 May 2026
- Published by Wroclaw Medical University in Dental and Medical Problems
- No. 5,p. 1155-1166
Open AccessOral microbiota diversity and composition in patients with oral lichen planus: An observational molecular analysis study
Oral lichen planus (OLP) is a chronic inflammatory condition affecting the oral mucosa. The oral microbiome has been identified as a potential contributing factor to OLP. The aim of the study was to evaluate the prevalence and diversity of the oral microbiota in patients with OLP. This observational study included 78 patients with clinically and histopathologically confirmed OLP, recruited in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Buccal mucosa samples were collected using standardized protocols. DNA was extracted from 12 high-quality samples and subjected to 16S rRNA gene amplification and sequencing. Alpha and beta diversity indices were calculated using the Quantitative Insights Into Microbial Ecology (QIIME) platform. Statistical analyses were performed using the IBM SPSS Statistics for Windows software, v. 26.0 (IBM Corp., Armonk, USA) (p < 0.05). Intratissue bacterial communities exhibited decreased alpha diversity and increased beta diversity compared with those present on the mucosal surface. Streptococcus, a genus within the Firmicutes phylum, was found to be the most abundant, with 5 Streptococcus strains identified in the OLP samples. Following Streptococci, Bacilli and Clostridia displayed considerable diversity. Other frequently detected species included Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Eikenella corrodens, Actinobacillus, as well as members of the Proteobacteria phylum, which are commonly found in high quantities in the oral cavity. Prevotella and Capnocytophaga, belonging to the Bacteroidetes phylum, were also frequently observed. Alpha diversity analysis revealed significant differences in the colony numbers of the investigated species across studied samples. The findings indicate an association between the composition of the oral microbiota and OLP. The microbial populations obtained from affected individuals exhibited distinct bacterial compositions. Modulation of the oral microbiome may represent a potential strategy for improving the management of OLP.
- Open Access
- 24 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-16
Enhanced antimicrobial efficacy and biocompatibility of albumin nanoparticles loaded with Mentha extract against methicillin resistant Staphylococcus aureus
In an effort to combat methicillin-resistant Staphylococcus aureus (MRSA), this study investigates the potential of mentha-loaded albumin nanoparticles (MLAN) as a novel antimicrobial agent. MLAN was synthesized by a desolvation method in which the mentha extract was encapsulated in albumin nanoparticles to increase stability and reduce toxicity. Characterization of the nanoparticles by transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR), dynamic light scattering (DLS), and X-ray Diffraction (XRD) confirmed their spherical morphology, a size range of 100–200 nm and uniform distribution. The encapsulation efficiency (EE%) and loading capacity (LC%) of MLAN were determined to be 80% and 72.73%, respectively, indicating a high effectiveness of the encapsulation process. Evaluation of cytotoxicity using the MTT assay revealed that MLAN exhibited significantly higher biocompatibility compared to aqueous Mentha extract and maintained cell viability at 85.1 ± 3.5% at the highest concentration tested (250 µg/mL). Antimicrobial evaluations against MRSA showed that MLAN had larger zones of inhibition and lower minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values (0.39 mg/mL and 0.78 mg/mL, respectively) compared to the aqueous extract (MIC: 0.78 mg/mL, MBC: 1.56 mg/mL). In addition, real-time PCR showed that MLAN significantly downregulated the expression of key virulence genes (icaA, icaD and ebps) in MRSA, indicating a potential reduction in bacterial virulence. These results suggest that MLAN could be a promising alternative to conventional antibiotics with improved antimicrobial efficacy and reduced cytotoxicity. The study underlines the potential of combining plant extracts with nanotechnology for the development of new therapeutic approaches against antibiotic-resistant pathogens such as MRSA. Further in vivo studies are warranted to validate the clinical applicability of MLAN.
- 24 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-16
Open AccessEnhanced antimicrobial efficacy and biocompatibility of albumin nanoparticles loaded with Mentha extract against methicillin resistant Staphylococcus aureus
In an effort to combat methicillin-resistant Staphylococcus aureus (MRSA), this study investigates the potential of mentha-loaded albumin nanoparticles (MLAN) as a novel antimicrobial agent. MLAN was synthesized by a desolvation method in which the mentha extract was encapsulated in albumin nanoparticles to increase stability and reduce toxicity. Characterization of the nanoparticles by transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR), dynamic light scattering (DLS), and X-ray Diffraction (XRD) confirmed their spherical morphology, a size range of 100–200 nm and uniform distribution. The encapsulation efficiency (EE%) and loading capacity (LC%) of MLAN were determined to be 80% and 72.73%, respectively, indicating a high effectiveness of the encapsulation process. Evaluation of cytotoxicity using the MTT assay revealed that MLAN exhibited significantly higher biocompatibility compared to aqueous Mentha extract and maintained cell viability at 85.1 ± 3.5% at the highest concentration tested (250 µg/mL). Antimicrobial evaluations against MRSA showed that MLAN had larger zones of inhibition and lower minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values (0.39 mg/mL and 0.78 mg/mL, respectively) compared to the aqueous extract (MIC: 0.78 mg/mL, MBC: 1.56 mg/mL). In addition, real-time PCR showed that MLAN significantly downregulated the expression of key virulence genes (icaA, icaD and ebps) in MRSA, indicating a potential reduction in bacterial virulence. These results suggest that MLAN could be a promising alternative to conventional antibiotics with improved antimicrobial efficacy and reduced cytotoxicity. The study underlines the potential of combining plant extracts with nanotechnology for the development of new therapeutic approaches against antibiotic-resistant pathogens such as MRSA. Further in vivo studies are warranted to validate the clinical applicability of MLAN.